title: [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
abstract: Subcutaneous nodules and neuropsychiatric complications are the most relevant adverse effects during apomorphine infusion treatment. Subcutaneous nodules appear in almost all the patients and accurate information and training of both patient and caregiver is essential to minimise their impact on the treatment. Although neuropsychiatric complications are not more frequent than with other dopaminergic treatments, they are linked with increasing difficulty of treatment and worsening of patient's quality of life.
authors.affiliation: Hospitales Universitarios Virgen del Rocio, 41013 Sevilla, Espana.
authors.forename: Verónica
authors.initials: V
authors.lastname: Giménez de Béjar
authors.forename: Manuel
authors.initials: M
authors.lastname: Carballo-Cordero
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001058:Apomorphine / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004198:Disease Susceptibility; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D006212:Hallucinations / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D055104:Infusions, Subcutaneous; D001523:Mental Disorders / Q000139:chemically induced* / Q000517:prevention & control; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D026741:Physical Therapy Modalities; D011595:Psychomotor Agitation / Q000188:drug therapy / Q000209:etiology; D011605:Psychoses, Substance-Induced / Q000209:etiology / Q000517:prevention & control; D012720:Severity of Illness Index; D012893:Sleep Wake Disorders / Q000139:chemically induced / Q000628:therapy
chemical_list: D000305:Adrenal Cortex Hormones; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D018491:Dopamine Agonists; D001058:Apomorphine